Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 4/2019

01-08-2019 | Acupuncture | Health Economics (N Khera, Section Editor)

Emerging Role of Integrative Medicine in Hematologic Malignancies: a Literature Review and Update on Current Trends in Complementary Medical Practices in Hematologic Cancers

Authors: Onyemaechi N. Okolo, Krisstina Gowin

Published in: Current Hematologic Malignancy Reports | Issue 4/2019

Login to get access

Abstract

Purpose of Review

This review discusses the emerging role of integrative hematology. It reinforces the growing interest of CAM among patients, and the importance of provider knowledge and participation in discussions with patients about the subject. The main question asked in this review, “Is there evidence for the use of integrative medicine practices in the field of malignant hematology?” is answered by examining current research and providing relevant summaries.

Recent Findings

Data suggests that practices such as meditative movement, exercise, nutrition and supplements and touch therapy can be used for symptom alleviation, preventive measures, and novel treatment development.

Summary

Integrative hematology is a needed part of complete patient care, and it is the role of providers to be knowledgeable and open to ensure patients are engaging in practices that are evidence-informed and safe. More studies are needed in the field in order to make concrete and robust recommendations.
Appendix
Available only for authorised users
Literature
1.
Rohan EA, Miller N, Bonner F, Fultz-Butts K, Pratt-Chapman ML, Alfano CM, et al. Comprehensive cancer control: promoting survivor health and wellness. Cancer Causes Control. 2018;29:1277–85.CrossRefPubMed
2.
Qureshi M, Zelinski E, Carlson LE. Cancer and complementary therapies: current trends in survivors’ interest and use. Integr Cancer Ther. 2018;17(3):844–53.CrossRefPubMedPubMedCentral
3.
• Kline RM, Arora NK, Bradley CJ, Brauer ER, Graves DL, Lunsford NB, et al. Long-term survivorship care after cancer treatment - summary of a 2017 National Cancer Policy Forum workshop. J Natl Cancer Inst. 2018. A study sponsored by the National Cancer Policy Forum of the National Academies of Sciences focusing on long-term survivorship care after treatment, which concluded, among other things, that there are substantial obstacles related to the routine delivery of standardized physical and psychosocial care services to patients and their families.;110:1300 10.CrossRefPubMed
4.
•• Witt CM, Balneaves LG, Cardoso MJ, et al. A comprehensive definition for integrative oncology. J Natl Cancer Inst Monogr. 2017;2017(52):lgx012 https://​doi.​org/​10.​1093/​jncimonographs/​lgx012. This paper identified that, although there are generally understood definitions of integrative oncology, there was no agreed upon official definition. By using a mixed-methods approach and an interdisciplinary expert panel, a definition was written and adopted.
5.
Deng G, Cassileth B. Integrative oncology: an overview. Am Soc Clin Oncol Educ Book. 2014;34:233–42.CrossRef
6.
Hack CC, Hüttner NBM, Hackl J, Fasching PA, Beckmann MW. Classification of integrative medicine: overview and significance in oncology. Gynakologe. 2017;50(1):9–14.CrossRef
7.
Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, Hershman D, et al. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr. 2014;2014(50):346–58.CrossRefPubMedPubMedCentral
8.
Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017;67(3):194–232.CrossRefPubMedPubMedCentral
9.
Abrams DI. An integrative approach to prostate cancer. J Altern Complement Med. 2018;24(9–10):872–80.CrossRefPubMed
10.
Oechsle K, Aslan Z, Suesse Y, Jensen W, Bokemeyer C, de Wit M. Multimodal exercise training during myeloablative chemotherapy: a prospective randomized pilot trial. Support Care Cancer. 2014;22(1):63–9.CrossRefPubMed
11.
• Cave J, Paschalis A, Huang CY, West M, Copson E, Jack S, et al. A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Support Care Cancer. 2018. A systematic review that showed that aerobic exercise either maintained or improved patient fitness during chemotherapy, and should be encouraged.;26:3337–51.CrossRefPubMed
12.
• Furzer BJ, Ackland TR, Wallman KE, Petterson AS, Gordon SM, Wright KE, et al. A randomised controlled trial comparing the effects of a 12-week supervised exercise versus usual care on outcomes in haematological cancer patients. Support Care Cancer. 2016;24(4):1697–707 A paper investigating the efficacy of a 12-week exercised rehabilitation program on cancer-related fatigue in patients with hematologic malignancy after receiving chemotherapy showed statistically significant outcomes and clinical improvement. CrossRefPubMed
13.
Streckmann F, Kneis S, Leifert JA, Baumann FT, Kleber M, Ihorst G, et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann Oncol. 2014;25(2):493–9.
14.
15.
Courneya KS, Friedenreich CM, Franco-Villalobos C, Crawford JJ, Chua N, Basi S, et al. Effects of supervised exercise on progression-free survival in lymphoma patients: an exploratory follow-up of the HELP Trial. Cancer Causes Control. 2015;26(2):269–76.CrossRefPubMed
16.
van Haren I, Staal JB, Potting CM, et al. Physical exercise prior to hematopoietic stem cell transplantation: a feasibility study. Physiother Theory Pract. 2018;34(10):747–56.CrossRefPubMed
17.
Bartels FR, Smith NS, Gorlov JS, et al. Optimized patient-trajectory for patients undergoing treatment with high-dose chemotherapy and autologous stem cell transplantation. Acta Oncol. 2015;54(5):750–8.CrossRefPubMed
18.
Jacobsen PB, Le-Rademacher J, Jim H, et al. Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. Biol Blood Marrow Transplant. 2014;20(10):1530–6.CrossRefPubMedPubMedCentral
19.
Keen C, Skilbeck J, Ross H, Smith L, Collins K, Dixey J, et al. Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation? Protocol for the PREeMPT study. BMJ Open. 2018;8(3):e021333.
20.
•• Yun H, Sun L, Mao JJ. Growth of integrative medicine at leading cancer centers between 2009 and 2016: a systematic analysis of NCI-designated comprehensive cancer center websites. J Natl Cancer Inst Monogr. 2017;2017(52):lgx004. https://​doi.​org/​10.​1093/​jncimonographs/​lgx004. An investigation via a systematic review of 45 NCI comprehensive cancer center websites, of the growth of integrative medicine in US academic cancer centers, which finds that more and more cancer centers are providing integrative medicine practices to their patients.
21.
Armstrong K, Lanni T, Anderson MM, Patricolo GE. Integrative medicine and the oncology patient: options and benefits. Support Care Cancer. 2018;26(7):2267–73.CrossRefPubMed
22.
Derry HM, Jaremka LM, Bennett JM, Peng J, Andridge R, Shapiro C, et al. Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial. Psychooncology. 2015;24(8):958–66.CrossRefPubMed
23.
Sprod LK, Fernandez ID, Janelsins MC, Peppone LJ, Atkins JN, Giguere J, et al. Effects of yoga on cancer-related fatigue and global side-effect burden in older cancer survivors. J Geriatr Oncol. 2015;6(1):8–14.
24.
25.
Salhofer I, Will A, Monsef I, Skoetz N. Meditation for adults with haematological malignancies. Cochrane Database Syst Rev. 2016;2:Cd011157.PubMed
26.
Huberty J, Eckert R, Gowin K, Mitchell J, Dueck AC, Ginos BF, et al. Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms. Haematologica. 2017;102(10):e384–8.CrossRefPubMedPubMedCentral
27.
Sattin RW, Easley KA, Wolf SL, Chen Y, Kutner MH. Reduction in fear of falling through intense tai chi exercise training in older, transitionally frail adults. J Am Geriatr Soc. 2005;53(7):1168–78.CrossRefPubMed
28.
Zeng Y, Luo T, Xie H, Huang M, Cheng AS. Health benefits of qigong or tai chi for cancer patients: a systematic review and meta-analyses. Complement Ther Med. 2014;22(1):173–86.CrossRef
29.
• Wayne PM, Lee MS, Novakowski J, Osypiuk K, Ligibel J, Carlson LE, et al. Tai Chi and qigong for cancer-related symptoms and quality of life: a systematic review and meta-analysis. J Cancer Surviv. 2018;12(2):256–67 A summary on the effects of tai chi and qigong (TCQ) on quality of life in cancer survivors showing that, although there are noted improvements in areas like fatigue and depression, more studies are needed. CrossRefPubMed
30.
Tang YY, Hölzel BK, Posner MI. The neuroscience of mindfulness meditation. Nat Rev Neurosci. 2015;16(4):213–25.
31.
32.
Kutner JS, Smith MC, Corbin L, Hemphill L, Benton K, Mellis BK, et al. Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial. Ann Intern Med. 2008;149(6):369–79.CrossRefPubMedPubMedCentral
33.
Frenkel M, Sapire K. Complementary and integrative medicine in hematologic malignancies: questions and challenges. Curr Oncol Rep. 2017;19(12):79.CrossRefPubMed
34.
Mehling WE, Lown EA, Dvorak CC, et al. Hematopoietic cell transplant and use of massage for improved symptom management: results from a pilot randomized control trial. Evid Based Complement Alternat Med. 2012;2012:450150.CrossRefPubMedPubMedCentral
35.
Davies E, Campbell S, Fullwood A, Hulbert J, Marks DI. The introduction of a holistic massage service in a combined paediatric and adult BMT unit. Bone Marrow Transplant. 2008;41(4):407–8.CrossRefPubMed
36.
Smith MC, Reeder F, Daniel L, Baramee J, Hagman J. Outcomes of touch therapies during bone marrow transplant. Altern Ther Health Med. 2003;9(1):40–9.PubMed
37.
Tarantino B, Earley M, Audia D, D’Adamo C, Berman B. Qualitative and quantitative evaluation of a pilot integrative coping and resiliency program for healthcare professionals. Explore (NY). 2013;9(1):44–7.CrossRef
38.
Marcus DA, Blazek-O’Neill B, Kopar JL. Symptomatic improvement reported after receiving Reiki at a cancer infusion center. Am J Hosp Palliat Care. 2013;30(2):216–7.CrossRefPubMed
39.
Birocco N, Guillame C, Storto S, Ritorto G, Catino C, Gir N, et al. The effects of Reiki therapy on pain and anxiety in patients attending a day oncology and infusion services unit. Am J Hosp Palliat Care. 2012;29(4):290–4.CrossRefPubMed
40.
•• Alarcão Z, Fonseca JRS. The effect of Reiki therapy on quality of life of patients with blood cancer: results from a randomized controlled trial. Eur J Integr Med. 2016;8(3):239–49 A Portuguese study to assess the effectiveness of Reiki on quality of life in patients with hematologic cancers, which suggests that Reiki may be effective and safe, and incorporable into the national health service. CrossRef
41.
•• Lyman GH, Bohlke K, Cohen L. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline summary. J Oncol Pract. 2018;14(8):495–9 ASCO endorsement of the Society of Integrative Oncology’s guidelines on the use of integrative therapies during and after breast cancer treatment. CrossRefPubMed
42.
•• Deng GE, Giralt S, Chung DJ, Landau HJ, Siman J, Search B, et al. Acupuncture for symptom reduction in myeloma patients undergoing hematopoietic stem cell transplantation: a randomized, sham-controlled trial. J Clin Oncol. 2017;35(15). A randomized sham-controlled trial evaluating the efficacy and safety of acupuncture in patients undergoing hematopoietic stem cell transplants that concluded that acupuncture is well tolerated and may reduce pain):8021.CrossRef
43.
Han X, Wang L, Shi H, Zheng G, He J, Wu W, et al. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. BMC Cancer. 2017;17(1):40.CrossRefPubMedPubMedCentral
44.
Bao T, Goloubeva O, Pelser C, Porter N, Primrose J, Hester L, et al. A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Integr Cancer Ther. 2014;13(5):396–404.CrossRefPubMedPubMedCentral
45.
Lu W, Rosenthal DS. Recent advances in oncology acupuncture and safety considerations in practice. Curr Treat Options in Oncol. 2010;11(3–4):141–6.CrossRef
46.
Fu H, Chen B, Hong S, Guo Y. Acupuncture therapy for the treatment of myelosuppression after chemotherapy: a literature review over the past 10 years. J Acupunct Meridian Stud. 2015;8(3):122–6.CrossRefPubMed
47.
Pais I, Correia N, Pimentel I, et al. Effects of acupuncture on leucopenia, neutropenia, NK, and B cells in cancer patients: a randomized pilot study. Evid Based Complement Alternat Med. 2014;2014:217397.CrossRefPubMedPubMedCentral
48.
Fortner RT, Katzke V, Kühn T, Kaaks R. Obesity and Breast Cancer. Recent Results Cancer Res. 2016;208:43–65.CrossRefPubMed
49.
Bertrand KA, Giovannucci E, Rosner BA, Zhang SM, Laden F, Birmann BM. Dietary fat intake and risk of non-Hodgkin lymphoma in 2 large prospective cohorts. Am J Clin Nutr. 2017;106(2):650–6.CrossRefPubMedPubMedCentral
50.
Shai A, Morr M, Uzan A, Koren O. Changes in the microbiome induced by adjuvant chemotherapy for breast and gynecological cancer and their association with weight gain. J Clin Oncol. 2018;36(15_suppl):e22113.CrossRef
51.
• Peled JU, Devlin SM, Staffas A, Lumish M, Khanin R, Littmann ER, et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncol. 2017;35(15):1650–9 A retrospective discovery-validation cohort study on patients following allo-HCT, showing that abundance of the gut bacteria, Eubacterium limosum , is associated with decreased risk of disease relapse and progression. CrossRefPubMedPubMedCentral
52.
Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One. 2010;5(5):e10667.CrossRefPubMedPubMedCentral
53.
Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140(2):197–208.CrossRefPubMedPubMedCentral
54.
Butturini AM, Dorey FJ, Lange BJ, Henry DW, Gaynon PS, Fu C, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007;25(15):2063–9.CrossRefPubMed
55.
Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005;293(2):203–11.CrossRefPubMed
56.
Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, et al. American Society of Clinical Oncology position statement on obesity and cancer. J Clin Oncol. 2014;32(31):3568–74.CrossRefPubMedPubMedCentral
57.
Ammann EM, Drake MT, Haraldsson B, Wallace RB, Johnson KC, Desai P, et al. Incidence of hematologic malignancy and cause-specific mortality in the Women’s Health Initiative randomized controlled trial of calcium and vitamin D supplementation. Cancer. 2017;123(21):4168–77.CrossRefPubMedPubMedCentral
58.
Chagas TR, Borges DS, de Oliveira PF, Mocellin MC, Barbosa AM, Camargo CQ, et al. Oral fish oil positively influences nutritional-inflammatory risk in patients with haematological malignancies during chemotherapy with an impact on long-term survival: a randomised clinical trial. J Hum Nutr Diet. 2017;30(6):681–92.CrossRefPubMed
59.
Kooti W, Servatyari K, Behzadifar M, Asadi-Samani M, Sadeghi F, Nouri B, et al. Effective medicinal plant in cancer treatment, part 2: review study. J Evid Based Complementary Altern Med. 2017;22(4):982–95.CrossRefPubMedPubMedCentral
60.
• Bahmani F, Esmaeili S, Bashash D, Dehghan-Nayeri N, Mashati P, Gharehbaghian A. Centaurea albonitens extract enhances the therapeutic effects of vincristine in leukemic cells by inducing apoptosis. Biomed Pharmacother. 2018;99:598–607 A study of the potential cytotoxic effects of Centaurea albonitens extract (CAE) alone and combined with vincristine in leukemic cells that shows that CAE is a potential anticancer agent, and an enhancer of vincristine chemotherapeutic effects. CrossRefPubMed
61.
Shanafelt TD, Drake MT, Maurer MJ, Allmer C, Rabe KG, Slager SL, et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 2011;117(5):1492–8.CrossRefPubMedPubMedCentral
62.
Kubeczko M, Nowara E, Spychalowicz W, et al. Efficacy and safety of vitamin D supplementation in patients with chronic lymphocytic leukemia. Postepy Hig Med Dosw (Online). 2016;70(0):534–41.CrossRef
63.
Liu P, Holman CDJ, Jin J, Zhang M. Green tea consumption is associated with a reduced risk of adult leukemia. Asia Pac J Clin Oncol. 2014;10:10.CrossRef
64.
Borutinskaitė V, Virkšaitė A, Gudelytė G, Navakauskienė R. Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells. Leuk Lymphoma. 2018;59(2):469–78.CrossRefPubMed
65.
• Pimentel-GutiéRrez HJ, Bobadilla-Morales L, Barba-Barba CC, et al. Curcumin potentiates the effect of chemotherapy against acute lymphoblastic leukemia cells via downregulation of NF-κ B. Oncol Lett. 2016;12(5):4117–24 Green Tea Catechin epigallocatechin-3-gallate (EGCG) may be able to halt cell proliferation, act as an epigenetic modifier, and even cause apoptosis in acute promyelocytic leukemia. CrossRefPubMedPubMedCentral
66.
Herviou L, Kassambara A, Boireau S, Robert N, Requirand G, Müller-Tidow C, et al. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs. Clin Epigenetics. 2018;10(1):121.CrossRefPubMedPubMedCentral
67.
Zhang Y, Kong Y, Liu S, Zeng L, Wan L, Zhang Z. Curcumin induces apoptosis in human leukemic cell lines through an IFIT2-dependent pathway. Cancer Biol Ther. 2017;18(1):43–50.CrossRefPubMedPubMedCentral
68.
Wu C, Ruan T, Liu W, Zhu X, Pan J, Lu W, et al. Effect and mechanism of curcumin on EZH2 - MiR-101 regulatory feedback loop in multiple myeloma. Curr Pharm Des. 2018;24(5):564–75.CrossRefPubMed
69.
Han TJ, Li JS, Luan XT, Wang L, Xu HZ. Dietary fat consumption and non-Hodgkin’s lymphoma risk: a meta-analysis. Nutr Cancer. 2017;69(2):221–8.CrossRefPubMed
70.
Metadata
Title
Emerging Role of Integrative Medicine in Hematologic Malignancies: a Literature Review and Update on Current Trends in Complementary Medical Practices in Hematologic Cancers
Authors
Onyemaechi N. Okolo
Krisstina Gowin
Publication date
01-08-2019
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 4/2019
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-019-00526-8

Other articles of this Issue 4/2019

Current Hematologic Malignancy Reports 4/2019 Go to the issue

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)

Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)

Targeting Translation of mRNA as a Therapeutic Strategy in Cancer

Chronic Lymphocytic Leukemias (N Jain, Section Editor)

Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL

CART and Immunotherapy (M Ruella and P Hanley, Section Editors)

Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era

CART and Immunotherapy (M Ruella and P Hanley, Section Editors)

Towards Automated Manufacturing for Cell Therapies

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)

Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits